C-reactive protein, advanced glycation end products, and their receptor in type 2 diabetic, elderly patients with mild cognitive impairment

Frontiers in Aging Neuroscience

Volumn 7, Issue OCT, 2015, Pages

  Gorska Ciebiada, Malgorzata ^a   Saryusz Wolska, Malgorzata ^a   Borkowska, Anna ^a   Ciebiada, Maciej ^a   Loba, Jerzy ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

AGEs; Cognitive impairment; Diabetes; Elderly; RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

AGE; AGED; ARTICLE; CARDIOVASCULAR DISEASE; COGNITION; COMORBIDITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMENTIA; DIABETIC PATIENT; DISEASE COURSE; DRUG USE; EDUCATIONAL STATUS; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MONTREAL COGNITIVE ASSESSMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; RETINOPATHY; STATISTICAL MODEL;

EID: 84946553400     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/fnagi.2015.00209     Document Type: Article

References (37)

1. Alagiakrishnan, K., Zhao, N., Mereu, L., Senior, P., and Senthilselvan, A. (2013). Montreal Cognitive Assessment is superior to standardized mini-mental status exam in detecting mild cognitive impairment in the middle-aged and elderly patients with type 2 diabetes mellitus. Biomed Res. Int. 11, 186106. doi: 10.1155/2013/186106.
2. Chen, G., Cai, L., Chen, B., Liang, J., Lin, F., Li, L., et al. (2011). Serum level of endogenous secretory receptor for advanced glycation end products and other factors in type 2 diabetic patients with mild cognitive impairment. Diabetes Care 34, 2586-2590. doi:10.2337/dc11-0958.
3. Cukierman, T., Gerstein, H. C., and Williamson, J. D. (2005). Cognitive decline and dementia in diabetes-systematic overview of prospective observational studies. Diabetologia 48, 2460-2469. doi:10.1007/s00125-005-0023-4.
4. Deane, R., and Zlokovic, B. V. (2007). Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease. Curr. Alzheimer Res. 4, 191-197. doi:10.2174/156720507780362245.
5. Eagan, D. E., Gonzales, M. M., Tarumi, T., Tanaka, H., Stautberg, S., and Haley, A. P. (2012). Elevated serum C-reactive protein relates to increased cerebral myoinositol levels in middle-aged adults. Cardiovasc Psychiatry Neurol 2012, 120540. doi:10.1155/2012/120540.
6. Ge, X., Xu, X. Y., Feng, C. H., Wang, Y., Li, Y. L., and Feng, B. (2013). Relationships among serum C-reactive protein, receptor for advanced glycation products, metabolic dysfunction, and cognitive impairments. BMC Neurol. 13:110. doi:10.1186/1471-2377-13-110.
7. Gorska-Ciebiada, M., Ciebiada, M., Barylski, M., and Loba, J. (2009). Diabetes mellitus in elderly according to new recommendations of Polish Diabetes Association. Geriatria 3, 147-150.
8. Gorska-Ciebiada, M., Saryusz-Wolska, M., Borkowska, A., Ciebiada, M., and Loba, J. (2015). Serum levels of inflammatory markers in depressed elderly patients with diabetes and mild cognitive impairment. PLoS ONE 10:e0120433. doi:10.1371/journal.pone.0120433.
9. Gorska-Ciebiada, M., Saryusz-Wolska, M., Ciebiada, M., and Loba, J. (2014). Mild cognitive impairment and depressive symptoms in elderly patients with diabetes-prevalence, risk factors and co-morbidity. J Diabetes Res 2014, 179648. doi:10.1155/2014/179648.
10. Haan, M. A., Aiello, A. E., West, N. A., and Jagust, W. J. (2008). C-reactive protein and rate of dementia in carriers and non carriers of apolipoprotein APOE4 genotype. Neurobiol. Aging 29, 1774-1782. doi:10.1016/j.neurobiolaging.2007.04.020.
11. Hori, O., Yan, S. D., Ogawa, S., Kuwabara, K., Matsumoto, M., Stern, D., et al. (1996). The receptor for advanced glycation end-products has a central role in mediating the effects of advanced glycation end-products on the development of vascular disease in diabetes mellitus. Nephrol. Dial. Transplant. 11, 13-16. doi:10.1093/ndt/11.supp5.13.
12. Katz, S., Downs, T. D., Cash, H. R., and Grotz, R. C. (1970). Progress in development of the index of ADL. Gerontologist 10, 20-30. doi:10.1093/geront/10.1_Part_1.20.
13. Kislinger, T., Fu, C., Huber, B., Qu, W., Taguchi, A., Du Yan, S., et al. (1999). N(epsilon)-(carboxymethyl) lysine modifications of proteins are ligands for RAGE that activate cell signalling pathways and modulate gene expression. J. Biol. Chem. 274, 31740-31749. doi:10.1074/jbc.274.44.31740.
14. Kumano-Kuramochi, M., Ohnishi-Kameyama, M., Xie, Q., Niimi, S., Kubota, F., Komba, S., et al. (2009). Minimum stable structure of the receptor for advanced glycation end product possesses multi ligand binding ability. Biochem. Biophys. Res. Commun. 386, 130-134. doi:10.1016/j.bbrc.2009.05.142.
15. Lawton, M. P., and Brody, E. M. (1969). Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9, 179-186. doi:10.1093/geront/9.3_Part_1.179.
16. Lue, L. F., Andrade, C., Sabbagh, M., and Walker, D. (2012). Is there inflammatory synergy in type II diabetes mellitus and Alzheimer's disease? Int. J. Alzheimers Dis. 2012, 918680. doi:10.1155/2012/918680.
17. Lue, L. F., Walker, D. G., Brachova, L., Beach, T. G., Rogers, J., Schmidt, A. M., et al. (2001). Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp. Neurol. 171, 29-45. doi:10.1006/exnr.2001.7732.
18. Marksteiner, J., Imarhiagbe, D., Defrancesco, M., Deisenhammer, E. A., Kemmler, G., and Humpel, C. (2014). Analysis of 27 vascular-related proteins reveals that NT-proBNP is a potential biomarker for Alzheimer's disease and mild cognitive impairment: a pilot-study. Exp. Gerontol. 50, 114-121. doi:10.1016/j.exger.2013.12.001.
19. Matsunaga-Irie, S., Maruyama, T., Yamamoto, Y., Motohashi, Y., Hirose, H., Shimada, A., et al. (2004). Relation between development of nephropathy and the p22phox C242T and receptor for advanced glycation end product G1704T gene polymorphisms in type 2 diabetic patients. Diabetes Care 27, 303-307. doi:10.2337/diacare.27.2.303.
20. Nasreddine, Z. S., Phillips, N. A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., et al. (2005). The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J. Am. Geriatr. Soc. 53, 695-699. doi:10.1111/j.1532-5415.2005.53221.x.
21. Neeper, M., Schmidt, A. M., Brett, J., Yan, S. D., Wang, F., Pan, Y. C., et al. (1992). Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem. 267, 14998-15004.
22. Petersen, R. C. (2004). Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 256, 183-194. doi:10.1111/j.1365-2796.2004.01388.x.
23. Portet, F., Ousset, P. J., Visser, P. J., Frisoni, G. B., Nobili, F., Scheltens, P., et al. (2006). Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer's Disease. J Neurol Neurosurg Psychiatry 77, 714-718. doi:10.1136/jnnp.2005.085332.
24. Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., and Hennekens, C. H. (1998). Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 97, 425-428. doi:10.1161/01.CIR.97.5.425.
25. Roberts, R. O., Geda, Y. E., Knopman, D. S., Boeve, B. F., Christianson, T. J., Pankratz, V. S., et al. (2009). Association of C-reactive protein with mild cognitive impairment. Alzheimers Dement. 9, 398-405. doi:10.1016/j.jalz.2009.01.025.
26. Ryan, C. M., and Geckle, M. (2000). Why is learning and memory dysfunction in type 2 diabetes limited to older adults? Diabetes Metab. Res. Rev. 16, 308-315. doi:10.1002/1520-7560(2000)9999:9999<::AID-DMRR141>3.0.CO;2-X.
27. Schmidt, A. M., Yan, S. D., Yan, S. F., and Stern, D. M. (2000a). The biology of the receptor for advanced glycation end products and its ligands. Biochim. Biophys. Acta 20, 99-111. doi:10.1016/S0167-4889(00)00087-2.
28. Schmidt, A. M., Hofmann, M., Taguchi, A., Yan, S. D., and Stern, D. M. (2000b). RAGE: a multiligand receptor contributing to the cellular response in diabetic vasculopathy and inflammation. Semin. Thromb. Hemost. 26, 485-493. doi:10.1055/s-2000-13204.
29. Schuitemaker, A., Dik, M. G., Veerhuis, R., Scheltens, P., Schoonenboom, N. S., Hack, C. E., et al. (2008). Inflammatory markers in AD and MCI patients with different biomarker profiles. Neurobiol. Aging 30, 1885-1889. doi:10.1016/j.neurobiolaging.2008.01.014.
30. Strachan, M. W. J., Deary, I. J., Ewing, F. M. E., and Frier, B. M. (1997). Is type II diabetes associated with a decline in cognitive function? A critical review of published studies. Diabetes Care 20, 438-445. doi:10.2337/diacare.20.3.438.
31. Ulrich, P., and Cerami, A. (2001). Protein glycation, diabetes, and aging. Recent Prog. Horm. Res. 56, 1-21. doi:10.1210/rp.56.1.1.
32. Wautier, M. P., Chappey, O., Corda, S., Stern, D. M., Schmidt, A. M., and Wautier, J. L. (2001). Activation of NADPH oxidase by AGEs links oxidant stress to altered gene expression via RAGE. Am. J. Physiol. Endocrinol. Metab. 280, E685-E694.
33. Wild, S., Roglic, G., Green, A., Sicree, R., and King, H. (2004). Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030. Diabetes Care 27, 1047-1053.
34. Win, M. T., Yamamoto, Y., Munesue, S., Saito, H., Han, D., Motoyoshi, S., et al. (2012). Regulation of RAGE for attenuating progression of diabetic vascular complications. Exp. Diabetes Res. 2012, 894605. doi:10.1155/2012/894605.
35. Yaffe, K., Lindquist, K., Penninx, B. W., Simonsick, E. M., Pahor, M., Kritchevsky, S., et al. (2003). Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology 61, 76-80. doi:10.1212/01.WNL.0000073620.42047.D7.
36. Yan, S. F., Ramasamy, R., and Schmidt, A. M. (2009). Receptor for AGE (RAGE) & its ligands-cast into leading roles in diabetes & the inflammatory response. J Mol Med (Berl) 87, 235-247. doi:10.1007/s00109-009-0439-2.
37. Yesavage, J., Brink, T., Rose, T., Lum, O., Huang, V., Adev, M., et al. (1982-1983). Development and validation of a geriatric depression screening scale: a preliminary report. J. Psychiatr. Res. 17, 37-49. doi:10.1016/0022-3956(82)90033-4.